PUBLISHER: QYResearch | PRODUCT CODE: 1867571
PUBLISHER: QYResearch | PRODUCT CODE: 1867571
The global market for Liquid Biopsy Products was estimated to be worth US$ 5142 million in 2024 and is forecast to a readjusted size of US$ 11449 million by 2031 with a CAGR of 12.4% during the forecast period 2025-2031.
Liquid biopsy products refer to a category of in vitro diagnostic tools that non-invasively analyze biomarkers such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosomes from blood, urine, or other body fluids for cancer screening, diagnosis, treatment monitoring, and recurrence prediction. These products span key steps such as sample collection, preservation, nucleic acid extraction, target detection, and data interpretation. Compared to traditional tissue biopsy, liquid biopsy offers advantages in safety, repeatability, and applicability across various cancer types, making it increasingly adopted in clinical settings and showing great potential in precision and personalized medicine.
The rapid global advancement of precision medicine and rising cancer incidence form a strong foundation for liquid biopsy adoption. National healthcare systems are increasingly incorporating liquid biopsy into cancer screening and targeted therapy workflows. The declining cost of next-generation sequencing (NGS) and enhanced interpretation capabilities through AI are accelerating product entry into multi-cancer detection and multicenter clinical validation.
Despite increasing technological maturity, liquid biopsy still faces challenges in balancing sensitivity and specificity, especially for early-stage cancer detection. Non-uniform standards in sample processing and reagent quality across upstream and downstream components complicate clinical translation. Regulatory hurdles around privacy and bioethics remain significant barriers for global expansion. Broker analyses highlight that most revenue still stems from research-grade orders, and wider clinical adoption and reimbursement pathways require further development.
Demand for liquid biopsy is rapidly shifting from research use to routine clinical applications. Monitoring therapeutic response and early relapse detection in high-incidence cancers-such as lung, breast, and colorectal-are driving hospital procurement. Collaboration between biotech companies and hospitals is deepening, with joint labs and multicenter studies becoming the norm. Annual reports also reflect growing patient awareness and preference for non-invasive testing, spurring product expansion into home-testing and mobile diagnostic scenarios.
This report aims to provide a comprehensive presentation of the global market for Liquid Biopsy Products, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Liquid Biopsy Products by region & country, by Type, and by Application.
The Liquid Biopsy Products market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Liquid Biopsy Products.
Market Segmentation
By Company
Segment by Type
Segment by Sample
Segment by Application
By Region
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Liquid Biopsy Products company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Liquid Biopsy Products in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Liquid Biopsy Products in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.